TP53 and soft tissue sarcoma: When we performed necropsies and histopathology on the tumors of the various tamoxifen treated CreERT2-p53F/F mice, we found that 3 and 6 month treated mice developed primarily lymphomas and secondarily soft tissue sarcomas, at ratios of roughly 2-3:1, similar to that of p53−/− mice (Fig. 3D).